Clinicopathologic Characteristics and Chemotherapy Response of Classic Hodgkin Lymphoma: A Study in Tertiary Teaching Hospital
Background and Objective: Hodgkin Lymphoma (HL) is known as a malignancy of the lymphatic system and 90% of the HL is Classic Hodgkin Lymphoma (CHL). Prognostic factors that identify the patient's response to therapy are useful for optimizing the therapy. This study aims to assess the clinicopathological characteristics and chemotherapy response associated with CHL patients.
Materials and Methods: This is a retrospective study of 40 patients diagnosed as CHL and treated with ABVD chemotherapy at Hasan Sadikin General Hospital/Padjadjaran University, Bandung, Indonesia during the period of January 2014 to December 2019. The clinicopathological characteristics data consisting of age, sex, histopathology subtype, tumor location and clinical stage were assessed. Their responses to chemotherapy were also analyzed.
Result and Discussion: A total of 40 patient data were included in this study, 21 CHL patients responded to ABVD chemotherapy (52.5%) while 19 patients not responded (47.5%). There were no significant association between age, sex, histopathological subtype, tumour location and clinical stage with chemotherapy response.
Conclusion: In this study, 47.5% of CHL patients did not respond to ABVD chemotherapy. The response of ABVD chemotherapy was not associated with age, sex, histopathological subtype, tumor location or clinical stage.
Keywords: Classic Hodgkin Lymphoma, chemotherapy response, clinicopathological characteristics.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov; 68(6):394-424.
3. GLOBOCAN. Indonesia. [database on the Internet]2018. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf.
4. Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018 May; 93(5):704-15.
5. Gerrie AS, Power MM, Shepherd JD, Savage KJ, Sehn LH, Connors JM. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Ann Oncol. 2014 Nov; 25(11):2218-23.
6. Kallam A, Vose JM. Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma. Oncology (Williston Park). 2019 May 14; 33(5):192-8.
7. Cuccaro A, Bartolomei F, Cupelli E, Galli E, Giachelia M, Hohaus S. Prognostic factors in hodgkin lymphoma. Mediterranean journal of hematology and infectious diseases. 2014; 6(1):e2014053-e.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan; 45(2):228-47.
9. Gerber NK, Atoria CL, Elkin EB, Yahalom J. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis. Int J Radiat Oncol Biol Phys. 2015 May 1; 92(1):76-83.
10. Sherief LM, Elsafy UR, Abdelkhalek ER, Kamal NM, Elbehedy R, Hassan TH, et al. Hodgkin lymphoma in childhood: clinicopathological features and therapy outcome at 2 centers from a developing country. Medicine. 2015 Apr; 94(15):e670.
11. Böll B, Görgen H. The treatment of older Hodgkin lymphoma patients. Br J Haematol. 2019 Jan; 184(1):82-92.
12. Huang X, Nolte I, Gao Z, Vos H, Hepkema B, Poppema S, et al. Epidemiology of classical Hodgkin lymphoma and its association with Epstein Barr virus in Northern China. PLoS One. 2011; 6(6):e21152.
13. Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. J Clin Oncol. 2012 Sep 20; 30(27):3383-8.
14. Mozaheb Z. Epidemiology of Lymphoid Malignancy in Asia. Epidemiology Insights, Maria de Lourdes Ribeiro de Souza da Cunha, IntechOpen. 2012.
15. Konkay K, Paul TR, Uppin SG, Rao DR. Hodgkin lymphoma: A clinicopathological and immunophenotypic study. Indian J Med Paediatr Oncol. 2016 Jan-Mar; 37(1):59-65.
16. Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA: a cancer journal for clinicians. 2018; 68(2):116-32.
17. Younes A. Handbook of Lymphoma. Switzerland: Springer International Publishing 2016.
18. Boo YL, Ting HSY, Yap DFS, Toh SG, Lim SM. Clinical features and treatment outcomes of Hodgkin lymphoma: A retrospective review in a Malaysian tertiary hospital. Blood Res. 2019; 54(3):210-7.
19. Shafi RG, Al-Mansour MM, Kanfar SS, Al Hashmi H, Alsaeed A, Al-Foheidi M, et al. Hodgkin Lymphoma Outcome: A Retrospective Study from 3 Tertiary Centers in Saudi Arabia. Oncology Research and Treatment. 2017; 40(5):288-92.
20. Guermazi A, Ooi CGG. Extranodal Hodgkin Disease. In: Guermazi A, editor. Radiological Imaging in Hematological Malignancies. Berlin, Heidelberg: Springer Berlin Heidelberg; 2004. p. 48-71.
21. Rueda Domínguez A, Márquez A, Gumá J, Llanos M, Herrero J, de Las Nieves MA, et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol. 2004 Dec; 15(12):1798-804.
22. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD. 1992; 327(21):1478-84.
23. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20; 31(6):684-91.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).